Mental Health Clinics in Mentor, OH Accepting Medicare
44 Mental Health Clinics found. Showing 41 - 44
 Hopebridge, Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 7325 Production Dr, Mentor, OH 44060 Phone: 855-324-0885 |
B. Sharif Md, Inc Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 8701 Mentor Ave, Mentor, OH 44060 Phone: 440-266-0770 Fax: 440-266-0257 |
Anna C Gray, Llc Counselor Medicare: Medicare Enrolled Practice Location: 8224 Mentor Ave Ste 208, Mentor, OH 44060 Phone: 440-622-3728 |
Live Well Counseling, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 7655 Mentor Ave # 311, Mentor, OH 44060 Phone: 440-375-1821 Fax: 216-744-1722 |
News Archive
FDA grants pediatric exclusivity for UCB's Keppra
UCB has announced that the US Food and Drug Administration (FDA) has granted pediatric exclusivity for Keppra (levetiracetam). The decision was based on pediatric data submitted to the FDA following a written request in 2001.
Study: Many gay and bisexual teenage boys use adult hookup apps to connect with friends, partners
Although hookup apps require users to be 18 or older, a new Northwestern Medicine study found that more than 50 percent of sexually active gay and bisexual boys ages 14 to 17 met male sexual partners on apps such as Grindr and Scruff.
New method for digital tissue diagnostics can streamline diagnosis and improve accuracy
The Swedish MedTech company Lumito is at its final stages of developing a new and unique method for digital tissue diagnostics that streamlines diagnosis and improves accuracy.
Sagent launches chemotherapy agent topotecan hydrochloride for injection
Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA approval and launch of its topotecan hydrochloride for injection, a chemotherapy agent, in conjunction with the innovator's patent expiry. Sagent's topotecan is available in 4 mg single-dose latex-free vials.
Ambit Biosciences raises $30 million through Series D-2 equity financing
Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.
› Verified 6 days ago